Patents Assigned to Pfizer
  • Publication number: 20040242666
    Abstract: The present invention relates to compounds of the Formula 1
    Type: Application
    Filed: May 12, 2004
    Publication date: December 2, 2004
    Applicants: Pfizer, Inc., Pfizer Products, Inc.
    Inventor: Yuhpyng Liang Chen
  • Publication number: 20040242587
    Abstract: This invention relates to substituted pyrrolo[1,2-b]pyridazine compounds of Formula I, 1
    Type: Application
    Filed: May 5, 2004
    Publication date: December 2, 2004
    Applicant: Pfizer Inc
    Inventor: Jian-Min Fu
  • Publication number: 20040241755
    Abstract: This invention relates to human chondrocyte activity (growth)/differentiation/production of extracellular matrix) and to the effect of Sox9 transcription factor and Col2 enhancer as a measure for such activity. It also relates to a chimeric cell and assay utilizing such cell useful in predicting the effect of sample compounds on chondrocyte activity as measured by Sox9 and Col2 expression/activity.
    Type: Application
    Filed: June 2, 2003
    Publication date: December 2, 2004
    Applicant: Pfizer Inc.
    Inventors: Leonard Buckbinder, Jean F. Schaefer
  • Publication number: 20040242569
    Abstract: Novel quaternary ammonium compounds of the formula 1
    Type: Application
    Filed: April 13, 2004
    Publication date: December 2, 2004
    Applicant: Pfizer Inc.
    Inventors: Patrick James Lennon, Dominique Francoise Bonafoux, Sergey Gregory Wolfson
  • Publication number: 20040242604
    Abstract: The invention relates to compounds of formula 1 1
    Type: Application
    Filed: May 20, 2004
    Publication date: December 2, 2004
    Applicant: Pfizer Inc
    Inventors: Samit Kumar Bhattacharya, Jinshan Chen, Richard Damian Connell, John Charles Kath, Goss S. Kauffman, Blaise S. Lippa, Joel Morris
  • Publication number: 20040242898
    Abstract: The present invention relates to a method of making novel dipeptidyl peptidase-IV (“DPP-IV’) inhibitor compounds useful for treating, inter alia, diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.
    Type: Application
    Filed: June 24, 2004
    Publication date: December 2, 2004
    Applicant: Pfizer Inc
    Inventor: Bernard Hulin
  • Patent number: 6825171
    Abstract: The invention relates to novel erythromycin derivatives, particularly ones with novel C-13 R13 substitutents, and to pharmaceutically acceptable salts thereof. The compounds of this invention are useful as antibacterial agents and antiprotozoa agents and for other applications (e.g., anticancer, atherosclerosis, gastric motility reduction, etc.) in mammals, including man, as well as in fish and. The invention also relates to pharmaceutical compositions containing such compounds and to methods of treating bacterial protozoa infections by administering such compounds. The invention also relates to methods of preparing such compounds and to intermediates useful in such preparation.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: November 30, 2004
    Assignee: Pfizer, Inc.
    Inventor: Yong-Jin Wu
  • Patent number: 6825193
    Abstract: The present invention is directed to a polymorph of the citrate salt of 4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one: and pharmaceutical compositions thereof.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: November 30, 2004
    Assignee: Pfizer Inc.
    Inventors: George J. Quallich, Lewin T. Wint
  • Patent number: 6825327
    Abstract: The invention relates to processes for preparing compounds of formula 1 wherein R3 is as defined herein, and to pharmaceutically acceptable salts thereof, as well as intermediates useful in such processes. The compounds of formula 1 are antibacterial agents that may be used to treat various bacterial and protozoa infections. The invention also relates to pharmaceutical compositions containing compounds prepared by the processes of the invention and to methods of treating bacterial protozoa infections by administering such compounds.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: November 30, 2004
    Assignee: Pfizer Inc.
    Inventors: Constantine Sklavounos, John L. Tucker, Lulin Wei, Kerry P. Mahon, Philip Hammen, Joanna T. Negri, Richard S. Lehner
  • Patent number: 6825344
    Abstract: There is provided a process for the preparation of a compound according to Formula (II): which includes the step of cyclising a compound of Formula (III): wherein R1, R2, R3, R4, X and m have meanings which are given in the description.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: November 30, 2004
    Assignee: Pfizer Inc.
    Inventors: Desmond John Best, George Burton, Brian Charles Gasson, Neal Frederick Osborne, Graham Walker
  • Patent number: 6825198
    Abstract: Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: November 30, 2004
    Assignee: Pfizer Inc
    Inventors: Phoebe Chiang, William A. Novomisle, Willard M. Welch, Jr.
  • Publication number: 20040235857
    Abstract: A novel solid form of sildenafil citrate wherein the ratio of sildenafil: citrate is 1:0.5.
    Type: Application
    Filed: January 22, 2004
    Publication date: November 25, 2004
    Applicant: Pfizer Inc
    Inventors: Christopher Ian Dallman, Andrew Kevern Hills, James Gerard McGovern, Richard Anthony Storey
  • Publication number: 20040235926
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the modulation of the cannabinoid receptors in animals are described herein.
    Type: Application
    Filed: May 3, 2004
    Publication date: November 25, 2004
    Applicant: Pfizer Inc.
    Inventor: Subas M. Sakya
  • Publication number: 20040236151
    Abstract: The invention relates to a method of preparing enantiomerically enriched amino alcohols of Formula I 1
    Type: Application
    Filed: March 19, 2004
    Publication date: November 25, 2004
    Applicant: Pfizer, Inc.
    Inventors: Steven P. Tanis, James A. Nieman
  • Publication number: 20040235833
    Abstract: The invention relates to indole derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The indole derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    Type: Application
    Filed: March 12, 2004
    Publication date: November 25, 2004
    Applicant: Pfizer Inc
    Inventors: Alan Daniel Brown, Justin Stephen Bryans, Mark Edward Bunnage, Paul Alan Glossop, Charlotte Alice Louise Lane, Russell Andrew Lewthwaite, Simon John Mantell
  • Publication number: 20040236084
    Abstract: The present invention provides substituted 2-aminopyridines of formula I, wherein R1, A1, W, X, and Y are as defined in the specification, useful in treating cell proliferative disorders.
    Type: Application
    Filed: January 16, 2004
    Publication date: November 25, 2004
    Applicant: Pfizer Inc
    Inventors: Cathlin Marie Biwersi, Dennis Joseph McNamara, Joseph Thomas Repine, Peter Laurence Toogood, Scott Norman Vanderwel, Joseph Scott Warmus
  • Publication number: 20040235856
    Abstract: The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of urinary incontinence, preferably mixed incontinence or stress urinary incontinence. The invention also relates to the use of antagonists of 5-HT2C receptors for the treatment of urine retention. The present invention also relates to a method of treatment of incontinence, to assays to screen for compounds useful in the treatment of incontinence, and to methods of preparing compositions for the treatment of urinary incontinence.
    Type: Application
    Filed: April 23, 2004
    Publication date: November 25, 2004
    Applicant: Pfizer Inc
    Inventors: Gordon McMurray, Wesley D. Miner
  • Publication number: 20040235759
    Abstract: Methods for treating or preventing bacterial or protozoal infections in mammals by administering a single dose of an antibiotic composition comprising a mixture of azalide isomers and a pharmaceutically acceptable vehicle are disclosed. Methods for increasing acute or chronic injection-site toleration in mammals by administering a single dose of antibiotic compositions comprising a mixture of azalide isomers and a pharmaceutically acceptable vehicle are also disclosed. A combination comprising: an antibiotic composition comprising a mixture of azalide isomers, a pharmaceutically acceptable carrier, and instructions for use in a single-dose administration is also disclosed.
    Type: Application
    Filed: December 23, 2003
    Publication date: November 25, 2004
    Applicant: Pfizer Inc
    Inventors: Peter Connor Canning, Wayne Alan Boettner
  • Publication number: 20040236105
    Abstract: The invention provides compounds of formula I,
    Type: Application
    Filed: March 26, 2004
    Publication date: November 25, 2004
    Applicant: Pfizer, Inc.
    Inventors: Stuart Green, Peter T. Stephenson, Charles W. Murtiashaw, Martha Murtiashaw
  • Patent number: D499023
    Type: Grant
    Filed: July 15, 1998
    Date of Patent: November 30, 2004
    Assignee: Pfizer, Inc.
    Inventors: Edward Michael Amos, Bruce Irvin Groves, Rodney L Laible